All In MedTech

Device Trial Radar · NCT01628198

Impact of Renal SympAthetic DenerVation on Chronic HypErtension

Last checked: Nov 20, 2026Latest source record: Jan 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

38

Actual

Start

Oct 2011

Primary completion

Aug 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Vivek ReddyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 26, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Despite the development of many drug therapies designed to treat high blood pressure (hypertension), it remains a considerable and poorly managed health, social and economic burden. For various reasons, including the high health care costs of treatment, there are estimates that up to 65% of patients with high blood pressure have untreated and/or uncontrolled blood pressure (BP). Aside from its effect on kidney function, chronic high blood pressure increases the risk for stroke, and heart disease. It is also thought to be involved in the formation of irregular heartbeats. This link between high blood pressure and heart health has been well described, as has their combined effect on the aging and the obesity-battling Western world. A recently published study (Symplicity HTN-2 trial) established the benefit of a new treatment procedure, catheter-based renal sympathetic denervation (RSDN) for hypertension, as having enormous potential for the treatment of patients with high blood pressure. This multi-center trial will attempt to confirm and expand on these promising data. Patients who enroll in the trial will be followed for 4 years.

Conditions

  • Uncontrolled Hypertension

Interventions

  • Celcius Thermacool Catheter or Chilli II Cooled Ablation CatheterDevice

    Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions. There are 2 devices that can be used---this is optional, based on physician preference: Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California or Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Ambulatory Systolic Blood PressureTime frame: baseline and 6 months
  2. Change in Ambulatory Diastolic Blood PressureTime frame: baseline and 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Icahn School of Medicine at Mount Sinai

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.